Previous Close | 2.1200 |
Open | 2.2300 |
Bid | 2.4600 x 900 |
Ask | 2.5400 x 1100 |
Day's Range | 2.0401 - 2.6400 |
52 Week Range | 1.6510 - 24.5000 |
Volume | |
Avg. Volume | 177,828 |
Market Cap | 1.476M |
Beta (5Y Monthly) | 0.81 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -22.2200 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for SXTC
TAIZHOU, China, Oct. 26, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that on October 19, 2023, NASDAQ notified us that it ha
Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on October 5, 2023TAIZHOU, China, Oct. 04, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("T
China SXT Pharmaceuticals ( NASDAQ:SXTC ) Full Year 2023 Results Key Financial Results Net loss: US$5.93m (loss widened...